

Ref: Syn/CS/SE/Reg 30/2025-26/Nov/12

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 8000

F +91 80 6891 8808

CIN: L85110KA1993PLC014937

www.syngeneintl.com

November 18, 2025

To,	To,	
The Manager,	The Manager,	
BSE Limited	National Stock Exchange of India Limited	
Corporate Relationship Department	Corporate Communication Department	
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051	
Scrip Code: 539268	Scrip Symbol: SYNGENE	

<u>Sub: Change in Senior Management Personnel - Disclosure under Regulation 30 of the Securities</u> and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A (7) of Part A of Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you of the following changes in organization structure of the Company.

- a. Mr. Alex Del Priore, Head of Large Molecules CDMO and a member of Executive Committee (Senior Management Personnel) will be leaving the Company by mutual consent with immediate effect.
- **b.** Appointment of Dr. Rohtash Kumar as Head of CDMO, Small and Large Molecule and a member of the Executive Committee (Senior Management Personnel) of the Company with effect from December 1, 2025.

The details required in terms of Regulation 30, Schedule III of the SEBI Listing Regulations and SEBI Circulars issued in this regard, are given in **Annexure – A**.

The above information will also be made available on the website of the Company at www.syngeneintl.com.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Chethan Yogesh
Company Secretary & Compliance Officer

Encl: a/a



Annexure A

<u>Details as required under Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are as under:</u>

S.	Particulars	Alex Del Priore	Rohtash Kumar
No.			
1.	Reason for change (viz. appointment, reappointment, resignation, removal, death or otherwise)	Mr. Alex Del Priore will be leaving the Company by mutual consent with immediate effect to pursue other career opportunities.	Appointment of Dr. Rohtash Kumar as Head of CDMO, Small and Large Molecule and a member of the Executive Committee (Senior Management Personnel) of the Company.
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Effective from November 18, 2025.	Effective from December 1, 2025
3.	Brief profile	Not Applicable.	Rohtash is an established pharmaceutical operations leader with over two decades of experience in R&D, manufacturing, and executive leadership across global CDMO organizations. Most recently, he led Global Technology and Development at Veranova, where he drove innovation in APIs, including small molecules, peptides, oligonucleotides, and biologics. His efforts successfully advanced branded API molecules to market in collaboration with biotech partners. A prolific researcher, Rohtash holds multiple patents and publications to his name. He earned his Ph.D. in Organic Chemistry from the University of Delhi, an M.Sc. in Organic Chemistry, and an MBA from Chaudhary Charan Singh University. Additionally, he is a member of the American, Canadian, and Indian Medical Societies.
4.	Disclosure of relationship (in case of appointment)	Not Applicable.	Not Applicable.